Psychopharmacology

, Volume 85, Issue 3, pp 346–352 | Cite as

Differential involvement of dopamine D-1 and D-2 receptors in the circling behaviour induced by apomorphine, SK & F 38393, pergolide and LY 171555 in 6-hydroxydopamine-lesioned rats

  • Jørn Arnt
  • John Hyttel
Original Investigations
Received:
Accepted:

Abstract

The antagonistic effect of dopamine (DA) D-1 and D-2 antagonists against circling behaviour induced by various DA agonists in 6-OHDA-lesioned rats has been investigated. DA D-1/D-2 selectivity of agonists in vitro was measured by the stimulatory effect on DA-sensitive adenylate cyclase in rat striatal homogenates (D-1), the inhibitory effect on electrically-induced release of 3H-DA in rabbit striatal slices (D-2) and the affinity to 3H-piflutixol (D-1) and 3H-spiroperidol (D-2) binding sites in rat striatal membranes. The contralateral circling behaviour induced by the DA D-1 agonist SK & F 38393 was blocked by the DA D-1 antagonist, SCH 23390, and by the mixed DA D-1/D-2 antagonist cis(Z)-flupentixol, but was not influenced by the DA D-2 antagonists spiroperidol and clebopride. In contrast, circling behaviour induced by the preferential DA D-2 agonists pergolide and LY 171555 was blocked by clebopride, spiroperidol, and cis(Z)-flupentixol, but weakly or not influenced by SCH 23390. Apomorphine-induced circling behaviour was blocked by cis(Z)-flupentixol, partially antagonized by SCH 23390 and clebopride but not inhibited by spiroperidol, although the time-course of circling was changed. Combinations of SCH 23390 with spiroperidol or clebopride in low doses completely blocked the effect of apomorphine. These results indicate that DA D-1 and D-2 receptors mediate circling behaviour through separate mechanisms which can be independently manipulated with respective agonists and antagonists. Furthermore, the results indicate that both DA D-1 and D-2 receptors are involved in the effect of apomorphine, since selective antagonists induced maximally 50% inhibition. Complete blockade was only found in combination experiments and by the mixed D-1/D-2 antagonists cis(Z)-flupentixol, cis(Z)-clopenthixol, and clozapine.

Key words

DA D-1 receptors DA D-2 receptors Circling behaviour Dopamine agonists Dopamine antagonists 6-OHDA lesions Rat 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arnt J, Hyttel J (1984) Differential inhibition by dopamine D-1 and D-2 antagonists of circling behaviour induced by dopamine agonists in rats with unilateral 6-hydroxydopamine lesions. Eur J Pharmacol 102:349–354Google Scholar
  2. Cheng, Y-C, Prusoff WH (1973) Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108Google Scholar
  3. Christensen AV, Arnt J, Hyttel J, Larsen J-J Svendsen O (1984) Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics. Life Sci 34:1529–1540Google Scholar
  4. Costall B, Naylor RJ, Pycock C (1976) Non-specific supersensitivity of striatal dopamine receptors after 6-hydroxydopamine lesion of the nigrostriatal pathway. Eur J Pharmacol 35:275–283Google Scholar
  5. Coward DM (1983) Apomorphine-induced biphasic circling behaviour in 6-hydroxydopamine-lesioned rats. A pharmacological kindling phenomenon. Naunyn-Schmiedeberg's Arch Pharmacol 323:49–53Google Scholar
  6. Fleminger S, Van de Waterbeemd H, Rupniak NMJ, Reavill C, Testa B, Jenner P, Marsden CD (1983) Potent lipophilic substituted benzamide drugs are not selective D-1 dopamine receptor antagonists in the rat. J Pharm Pharmacol 35:363–368Google Scholar
  7. Fuller RW, Clemens JA, Hynes III MD (1982) Degree of selectivity of pergolide as an agonist at presynaptic versus or treatment of tardive dyskinesia. J Clin Psychopharmacol 2:371–375Google Scholar
  8. Fuller RW, Hemrick-Luecke SK, Wong DT, Pearson D, Threlkeld PG, Hynes III MD (1983) Altered behavioral response to a D2 agonist, LY 141865, in spontaneously hypertensive rats exhibiting biochemical and endocrine responses similar to those in normotensive rats. J Pharmacol Exp Ther 227:354–359Google Scholar
  9. Gershanik O, Heikkila RE, Duvoisin RC (1983) Behavioral correlations of dopamine receptor activation. Neurology 33:1489–1492Google Scholar
  10. Goldstein M, Lieberman A, Lew JY, Asano K, Rosenfeld MR, Makman MH (1980) Interaction of pergolide with central dopaminergic receptors. Proc natl Acad Sci USA 77:3725–3728Google Scholar
  11. Gower AJ, Marriott AS (1982) Pharmacological evidence for the subclassification of central dopamine receptors in the rat. Br J Pharmacol 77:185–194Google Scholar
  12. Herrera-Marschitz M, Ungerstedt U (1984) Evidence that apomorphine and pergolide induce rotation in rats by different actions on D1 and D2 receptor sites. Eur J Pharmacol 98:165–176Google Scholar
  13. Hyttel J (1978) Effects of neuroleptics on 3H-haloperidol and 3H-cis(Z)-flupenthixol binding and on adenylate cyclase activity in vitro. Life Sci 23:551–556Google Scholar
  14. Hyttel J (1980) Further evidence that 3H-cis(Z)-flupenthixol binds to the adenylate cyclase-associated dopamine receptor (D-1) in rat corpus striatum. Psychopharmacology 67:107–109Google Scholar
  15. Hyttel J (1981a) Similarities between the binding of 3H-piflutixol and 3H-flupentixol to rat striatal dopamine receptors in vitro. Life Sci 28:563–569Google Scholar
  16. Hyttel J (1981b) Flupentixol and dopamine receptor selectivity. Psychopharmacology 75:217Google Scholar
  17. Hyttel J (1982) Preferential labelling of adenylate cyclase coupled dopamine receptors with thioxanthene neuroleptics. In: Kohsaka M, Shohmori T, Tsukuda Y, Woodruff GN (eds) Advances in dopamine research. Pergamon Press, Oxford, Advances in the Biosciences. pp 147–152Google Scholar
  18. Hyttel J (1983) SCH 23390—the first selective dopamine D-1 antagonist. Eur J Pharmacol 91:153–154Google Scholar
  19. Iorio LC, Barnett A, Leitz FH, Houser VP, Korduba CA (1983) SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J Pharmacol Exp Ther 226:462–468Google Scholar
  20. Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277:93–96Google Scholar
  21. Koller WC, Weiner WJ, Diamon BI, Nausieda PA, Klawans HL (1980) The pharmacological evaluation of pergolide mesylate as a potential anti-parkinson agent. Neuropharmacology 19:831–837Google Scholar
  22. König JFR, Klippel RA (1963) The rat brain. Williams and Wilkins, BaltimoreGoogle Scholar
  23. Kozlowski MR, Sawyer S, Marshall JF (1980) Behavioural effects and supersensitivity following nigral dopamine receptor stimulation. Nature 287:52–54Google Scholar
  24. Lehmann J, Briley M, Langer SZ (1983) Characterization of dopamine autoreceptor and [3H]-spiperone binding sites in vitro with classical and novel receptor agonists. Eur J Pharmacol 38:11–26Google Scholar
  25. Oberlander C, Dumont C, Boissier JR (1980) Time course of apomorphine-induced circling behaviour after striatal dopamine receptor denervation. Eur J Pharmacol 62:107–110Google Scholar
  26. O'Boyle KM, Pugh M, Waddington JL (1984) Stereotypy induced by the D2 dopamine agonist RU24213 is blocked by the D2 antagonist RO22-2586 and the D1 antagonist SCH 23390. Br J Pharmacol 82:242Google Scholar
  27. Setler PE, Sarau HM, Zirkle CL, Saunders HL (1978) The central effects of a novel dopamine agonist. Eur J Pharmacol 50:419–430Google Scholar
  28. Starke K, Späth L, Lang JD, Adelung C (1983) Further functional in vitro comparison of pre-and postsynaptic dopamine receptors in the rabbit caudate nucleus. Naunyn Schmiedeberg's Arch Pharmacol 323:298–306Google Scholar
  29. Starr MS, Summerhayes M (1982) Multifocal brain sites for apomorphine-induced circling and other stereotyped motor behaviour in the 6-hydroxydopamine-lesioned rat. Neurosci Lett 34:277–282Google Scholar
  30. Stoof JC, Kebabian JW (1982) Independent in vitro regulation by the D-2 dopamine receptor of dopamine-stimulated efflux of cyclic AMP and K+-stimulated release of acetylcholine from rat neostriatum. Brain Res 250:263–270Google Scholar
  31. Titus RD, Kornfeld EC, Jones ND, Clemens JA, Smalstig EB, Fuller RW, Hahn RA, Hynes III MD, Mason NR, Wong DT, Foreman MM (1983) Resolution and absolute configuration of an ergoline-related dopamine agonist, trans-4,4a,5,6,7,8,8a,9-octahydro-5-propyl-1H (or 2H)-pyrazolo[3,4-g]quinoline. J Med Chem 26:1112–1116Google Scholar
  32. Tsuruta K, Frey EA, Grewe CN, Cote TE, Eskay RL, Kebabian JW (1981) Evidence that LY 141865 specifically stimulates the D-2 dopamine receptor. Nature 292:463–465Google Scholar
  33. Ungerstedt U (1971) Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367:69–93Google Scholar
  34. Usuda S, Nishikori K, Noshiro O, Maeno H (1981) Neuroleptic properties of cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-09151-2) with selective antidopaminergic activity. Psychopharmacology 73:103–109Google Scholar
  35. Wong DT, Reid LR (1980) Activation of adenylate cyclase in rat striatum by an ergoline dopamine agonist, pergolide. Commun Psychopharmacol 4:269–275Google Scholar
  36. Wong DT, Bymaster EP, Reid LR, Fuller RW, Perry KW, Kornfeld EC (1983) Effect of a stereospecific D2-dopamine agonist on acetylcholine concentration in corpus striatum of rat brain. J Neural Transm 58:55–67Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • Jørn Arnt
    • 1
  • John Hyttel
    • 1
  1. 1.Department of Pharmacology and toxicologyH. Lundbeck A/SCopenhagen-ValbyDenmark

Personalised recommendations